戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  potential to shift the paradigm of clinical mycology.
2 ions presents a growing challenge in medical mycology.
3 of routine laboratory performance in medical mycology.
4 ether with its growth alongside the field of mycology.
5 l to face the growing challenges in clinical mycology.
6 olecular testing for Aspergillus in clinical mycology.
7  improve and streamline the work flow in the mycology and clinical microbiology laboratory.
8 e Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097377/Z/11/Z and the Dan
9  the 2020 European Confederation for Medical Mycology and the International Society for Human and Ani
10 drugs, more training in the field of medical mycology, and better funding for research and provision
11   Growth was detected in all BacT and Bactec mycology bottles, all BacT aerobic bottles, and by termi
12 6 (27%) anaerobic bottles, and 210/216 (97%) mycology bottles.
13 n method developed at the Center for Medical Mycology, Cleveland, Ohio, for testing the susceptibilit
14  testing developed at the Center for Medical Mycology, Cleveland, Ohio.
15                            Of 3,855 positive mycology cultures (yeast, 82%; molds, 18%), 62 (1.6%) we
16 rmine the benefit of a 4-week incubation for mycology cultures, we evaluated all positive cultures du
17 tion sequencing to address a gap in clinical mycology diagnostics and antifungal susceptibility testi
18 as not been utilized extensively in clinical mycology due to challenges in developing an effective pr
19 is and the European Confederation of Medical Mycology (ECMM) and the International Society for Human
20 SCMID) and European Confederation of Medical Mycology (ECMM) grading system, which are summarised in
21 ive of the European Confederation of Medical Mycology (ECMM).
22 using the European Confederation for Medical Mycology (ECMM)/International Society for Human and Anim
23 e International Society for Human and Animal Mycology (ECMM/ISHAM) consensus case definitions.
24 y/International Society for Human and Animal Mycology (ECMM/ISHAM) criteria.
25                             Here, we combine mycology, embryology and chemistry by testing secondary
26 ements for European Confederation of Medical Mycology Excellence Centre blue status.
27 , and his interests included plant diseases, mycology, forest insects, white pine blister rust, the m
28                          Research in medical mycology has traditionally been a mix of exciting biolog
29                      Innovations in clinical mycology, however, have remained limited, particularly i
30  the 2020 European Confederation for Medical Mycology/International Society for Human and Animal Myco
31 e International Society for Human and Animal Mycology (ISHAM) COVID-19-associated pulmonary aspergill
32 o alert clinicians and personnel in clinical mycology laboratories of the pathogenicity of this organ
33                 Direct isolation could allow mycology laboratories to more rapidly identify Candida s
34 of yeast species commonly encountered in the mycology laboratory at Mayo Clinic is described here.
35 tion of filamentous fungi encountered in the mycology laboratory at the Mayo Clinic.
36  our routine workflow has revolutionized our mycology laboratory efficiency, with improved accuracy a
37 nsive reviews of certain aspects of clinical mycology laboratory testing to provide a broader context
38 atophytes commonly encountered in a clinical mycology laboratory-Trichophyton mentagrophytes, Trichop
39 ntification of dermatophytes in the clinical mycology laboratory.
40 ny growth, which would be used in a clinical mycology laboratory.
41                  The aerobic, anaerobic, and mycology media for each system were evaluated: Bactec Pl
42 des of simulated candidemia when specialized mycology media were used.
43 on Czapek Dox agar but are absent on routine mycology media, where only chlamydospores are observed.
44 y addresses this issue by evaluating medical mycology OPT and comparing its fungal specimen identific
45 ratories participating in the New York State mycology OPT from 1982 to 1994 were compared with the id
46 at accompany yeast isolates submitted to the Mycology Reference Laboratory (United Kingdom) for eithe
47 riensis were submitted to the United Kingdom Mycology Reference Laboratory for identification.
48 east species submitted to the United Kingdom Mycology Reference Laboratory over a 2-year period.
49 ive isolates of C. albicans submitted to the Mycology Reference Laboratory over a 9-month period.
50 n 11 March and 14 July 2020, the UK National Mycology Reference Laboratory received 1,267 serum and r
51 s agents of mucormycosis and referred to the Mycology Reference Laboratory, Bristol, UK, for speciati
52 rphologic classification when performed by a mycology reference laboratory, but a higher rate of mism
53 s are in place for the next phase of medical mycology research: defining the virulence-associated fac
54 icin B and a broad-spectrum triazole pending mycology results) among patients with suspicious wounds.
55  From assistant mycologist in the Section of Mycology to Chief of the Bureau of Plant Industry to Ass